SCHEMBL4247732

SCHEMBL4247732

CCN(CC)CCOC(=O)c1ccc(NC(=O)c2cccc(OC)c2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.73
KMT2A Q03164 7/20 0.73
MEN1 O00255 6/20 0.73
TP53 P04637 5/20 0.67
NPC1 O15118 3/20 0.67
RAB9A P51151 3/20 0.67
ALDH1A1 P00352 3/20 0.67
PKM P14618 1/20 0.67
HPGD P15428 1/20 0.67
MAPK1 P28482 1/20 0.67
MAPT P10636 3/20 0.62
KDM4E B2RXH2 1/20 0.58
TSHR P16473 1/20 0.58
NFKB1 P19838 1/20 0.58
NFKB2 Q00653 1/20 0.58
RELA Q04206 1/20 0.58
MCHR1 Q99705 1/20 0.57
KDR P35968 1/20 0.55
LMNA P02545 1/20 0.54
AR P10275 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4252179 0.84 ALDH1A1 (0.62) SMN1; SMN2KMT2AMEN1TP53NPC1
SCHEMBL5582633 0.80 SMN1; SMN2 (0.69) SMN1; SMN2KMT2AMEN1NPC1RAB9A
SCHEMBL1499499 0.79 KMT2A (0.66) SMN1; SMN2KMT2AMEN1TP53NPC1
SCHEMBL3079077 0.79 MAPT (0.62) SMN1; SMN2KMT2AMEN1TP53NPC1
SCHEMBL3364980 0.77 HPGD (0.68) SMN1; SMN2KMT2AMEN1TP53NPC1
SCHEMBL9865362 0.77 SMN1; SMN2 (0.65) SMN1; SMN2TP53NPC1RAB9AALDH1A1
SCHEMBL6802217 0.77 NPC1 (0.83) SMN1; SMN2KMT2AMEN1TP53NPC1
SCHEMBL14082932 0.77 MAPT (0.63) SMN1; SMN2KMT2AMEN1TP53NPC1
SCHEMBL1525896 0.76 MEN1 (0.60) SMN1; SMN2KMT2AMEN1TP53NPC1
SCHEMBL1499350 0.76 KMT2A (0.60) SMN1; SMN2KMT2AMEN1TP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036420-A1 BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS GABBR1, GABBR2, CHRM2 SMN1; SMN2 155/4885KMT2A 632/4885MEN1 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.